中国肺癌杂志2018，Vol.21Issue(5)：428-430,3.DOI:10.3779/j.issn.1009-3419.2018.05.13
安罗替尼治疗KRAS突变型晚期肺腺癌1例
A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation Treated with Anlotinib
摘要
Abstract
In recent years, the number of advanced non-small cell lung cancer (NSCLC) patients has gradually increased, and the treatment methods have also been significantly increased. However, there are no standard treatment plans at home and abroad for third-line and above patients who are refractory to targeted therapy epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) or chemotherapy. The clinical treatment effect is also not satisfactory. Anlotinib is a novel TKI targeting the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit. ALTER0303 trail, phase III study has demonstrated that Anlotinib significantly prolonged overall survival (OS) and progression-free survival (PFS) in advanced NSCLC patients as 3rdline treat-ment.Here we report a case of advanced lung adenocarcinoma harboring KRAS mutation treated with Anlotinib.关键词
安罗替尼(Anlotinib)/肺肿瘤/晚期肺癌Key words
Anlotinib/Lung neoplasms/Advanced lung cancer引用本文复制引用
苏雨栋,孟昭婷,徐晓燕,王心悦,左冉,侯云霞,李凯,陈鹏..安罗替尼治疗KRAS突变型晚期肺腺癌1例[J].中国肺癌杂志,2018,21(5):428-430,3.基金项目
本文受天津市科委面上项目(No.13JCYBJC23600)和天津市卫生局科技基金(No.2015KZ085)资助This work was supported by funding from the Natural Science Foundation of Tianjin (No.13JCYBJC23600) and the Science and Technique Foundation of Tianjin Public Health Bureau (all to Peng CHEN)(No.2015KZ085). （No.13JCYBJC23600）
